

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 April 2002 (11.04.2002)

PCT

(10) International Publication Number
WO 02/28819 A1

(51) International Patent Classification⁷: C07C 233/65. (74) Agents: KADLE, Ranjana et al.; Hodgson Russ LLP, One M & T Plaza, Suite 2000, Buffalo, NY 14203-2391 (US).

(21) International Application Number: PCT/US01/42436

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, H, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 2 October 2001 (02.10.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/237,319 2 October 2000 (02.10.2000) US

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK [US/US]; State University of New York at Buffalo, Suite 200, UB Commons, 520 Lee Entrance, Amherst, NY 14228 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): COBURN, Robert, A. [US/US]; 35 Chestnut Hill S., Williamsville, NY 14221 (US). EVANS, Richard, T. [US/US]; 38 Fiddler's Green, East Amherst, NY 14051 (US). GENCO, Robert, J. [US/US]; 32 St. Catherine's Court, Buffalo, NY 14222 (US).

WO 02/28819 A1

(54) Title: NAPHTHYLSALICYLANILIDES AS ANTIMICROBIAL AND ANTIINFLAMMATORY AGENTS

(57) Abstract: The present invention discloses novel naphthylsalicylanilides of the general formula (I) wherein W is a substituted or unsubstituted naphthyl ring. The substitution on W includes replacing one or more -H with -OH, alkyl O-alkyl, branched alkyl, or cycloalkyl, containing 1-6 carbon atoms or combinations thereof. Y is a substituted or unsubstituted phenyl ring or substituted or unsubstituted naphthyl ring. The substitution for Y includes replacement of one or more -H atoms with Cn, CF₃, NO₂, methoxy, benzoyl, phenoxy, phenoxy methyl or combinations thereof. These compounds are useful as antibacterial against gram negative and gram positive bacteria and as antiinflammatory agents.

BEST AVAILABLE COPY

**NAPHTHYLSALICYLANILIDES AS ANTIMICROBIAL AND
ANTIINFLAMMATORY AGENTS**

This application claims priority of U.S. provisional application serial no. 60/237,319, filed on October 2, 2000, the disclosure of which is incorporated herein by reference.

5

FIELD OF INVENTION


10 The present invention relates generally to the field of antimicrobial agents. More particularly, the present invention provides novel naphthylsalicylanilides and a method for the use of these compounds as antimicrobial and antiinflammatory agents.

DISCUSSION OF RELATED ART

15 Several Salicylanilide compounds have been identified as potential antimicrobial agents. Previously, some of these agents have been shown to be effective against microorganisms associated with dental plaques.

20 U.S. Patent no. 4,287,191 discloses 5-acylsalicylanilides which are said to be effective antiseptics against a wide range of microorganisms, especially bacteria and the microorganisms prevalent in dental plaque. However, these compounds were not found to be effective against antibiotic resistant bacteria 25 such as *S.mutans*. The general structure of these compounds can be represented by the following formula:

30



35

- 2 -

Wherein Z is a substituted phenyl ring, R is a substituted or unsubstituted alkyl or phenyl group and X is -CN, -F, NO₂, -H, lower alkyl or lower haloalkyl.

U.S. patent no. 4,358,443 discloses 5-alkylsalicylanilides having the same general formula as above wherein R is a substituted or unsubstituted -alkyl or phenyl group.

U.S. patent no. 4,939,132 discloses 5-sulfonylalkylsalicylanilides as antimicrobials having the same general formula as above wherein R is a substituted or unsubstituted alkylsulfonyl group.

U.S. patent nos. 4,742,083 and 5,958,911 disclose antiinflammatory effects of salicylanilides.

Given the constant emergence of antibiotic resistant bacteria, there is an ongoing need for novel antimicrobial agents effective against a wide variety of bacteria.

SUMMARY OF THE INVENTION

The present invention provides novel aroylsalicylanilides. In particular, the present invention provides novel 5-naphthylsalicylanilides and describes the antimicrobial effects of these compounds against a wide variety of bacteria. Further, this invention also provides a method of using these compounds for obtaining relief from infections associated with the bacteria.

Accordingly, it is an object of the invention to provide novel naphthylsalicylanilides.

Another object of the present invention is to provide a method for the use of naphthylsalicylanilides as antimicrobial agents.

A yet another object of the present invention is to provide a method for the control of periodontal disease.

35

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a representation of the effect of naphthylsalicylanilides and TMF-12 on the ear weights in a mouse ear inflammation assay.

5 DETAILED DESCRIPTION OF THE INVENTION

Definitions

By the term "partition coefficient" as used herein for the purposes of specification and claims is meant the $\log_{10}P$ where P is the ratio of the molar

10 concentrations of the compositions of the composition in octanol-water system. Partition coefficient is a measure of the lipophilic character of the compound. A partition coefficient of 4 therefore means that the ratio of the concentration of the composition in octanol
15 to the concentration in water is 10⁴ or 10,000 to 1.


By the term "high lipophilicity" as used herein for the purposes of specification and claims is meant a partition coefficient greater than 4.

20 By the term "substituted" as used herein for the purposes of specification and claims is meant that one or more hydrogens atoms in the compound is replaced with a carbon and/or nitrogen containing moiety such as, but not limited to, alkyl, O-alkyl, branched alkyl, cycloalkyl (all alkyl groups containing 1-6 carbon atoms), CN, CF₃, NO₂, methoxy, phenoxy, benzoyl, phenoxyethyl and combinations thereof.

25 The present invention is based on the unexpected observation that 5-naphthylsalicylanilides were observed to be more effective antibacterial agents than the 5-
30 acyl or 5-alkyl salicylanilides disclosed in U.S. patents 4,287,191 and 4,352,443. The compounds of the present invention are encompassed by the following formula (designated herein as Formula 100).

- 4 -

5




wherein W is a substituted or unsubstituted naphthyl ring. The substitution on W includes replacing one or more -H with -OH, alkyl, O-alkyl, branched alkyl, or cycloalkyl, containing 1-6 carbon atoms or combinations thereof. Y is a substituted or unsubstituted phenyl ring or substituted or unsubstituted naphthyl ring. The substitution for Y includes replacement of one or more -H atoms with CN, CF₃, NO₂, methoxy, benzoyl, phenoxy, phenoxyethyl or combinations thereof.

In one embodiment, wherein Y is substituted or unsubstituted phenyl group, and W is unsubstituted naphthyl group, the compounds of the present invention may be represented by the following formula (Formula 110) :

25


30



Wherein Z represents the substitution on the phenyl ring. Z is preferably an electron withdrawing group and desirably is not strongly hydrophilic or water


solublizing. In one embodiment, Z is independently at each location -H, -CF₃, -CN or -NO₂. When Z is H at each position, the compound is designated herein as NA1. When Z is -CF₃ at the meta position, the compound has the 5 following structure:

10



20


25



This compound is designated herein as NA1mC (α isomer; attachment at the naphthalene 1-position) or NA2mC (β isomer; attachment at the naphthalene 2-position). When the -CN group is at the para position, the compound is referred to herein as NA1pC (α isomer) or NA2pC (β isomer). Similar isomers for other compounds of the present invention are intended to be within the scope of 30 35 this invention.

In another embodiment, Z may be a methoxy, phenoxy, benzoyl or phenoxyethyl group. An example when Z is a phenoxyethyl group is as follows.

5




20

This compound is referred to herein as NA1_3BnOPh.

In another embodiment, the Z substitution is at both the meta positions. An example of a disubstituted compound is as follows, designated herein as NA1mF2.


25

30



In another embodiment, Y is an unsubstituted or substituted naphthyl ring. An example of a compound when Y is a substituted naphthyl ring is as follows (designated as NA1NpC).


5



10

In another embodiment, the naphthyl group W of the naphthylsalicylanilides of Formula 100 may substituted. An example of such a substitution is wherein a -H is 15 substituted by -OH.

20



This compound is referred to herein as NA1OHmF.

25

The compounds of the present invention can be synthesized by a two-step process where the first step prepares the ester to be used for all similar (such as 1-naphthoyl) derivatives with the same aroyl group. In the second step the desired anilide is prepared by 30 reacting the ester with the aniline or aniline derivative.

An advantage of the compounds of the present invention is that they have unexpectedly higher potency than the salicylanilides described previously (U.S.

- 8 -

Patent 4,287,191; 4,358,443 and 4,939,132). In the compounds of the present invention, the 5-naphthyl groups are connected to the salicylanilides via a carbonyl group.

5 The introduction of the naphthyl group at the 5-position renders them effective against a wide range of bacteria. Thus, the compounds of the present invention have been found to be effective against both gram positive and gram negative bacteria. These gram 10 positive bacteria include, but are not limited to, *Streptococcus mutans*, *Streptococcus sanguis*, *Micrococcus luteus*, *Streptococcus salivarius*, *Propionibacterium acnes*, *Actinomyces viscosus*, *Staphylococcus aureus*, *Lactobacillus rhamnosus* (casei) 7469. The gram negative 15 bacteria include, but are not limited to, *Salmonella*, *Fusobacterium nucleatum* 25586, *Actinobacillus actinomycetemcomitans* (Aa) Y4, *Escherichia coli*, *Porphyromonas gingivalis*, *Salmonella cholerasuis* (Sal. chsuis), *Bacteroides fragilis* and *Citrobacter*.

20 Since these compounds are highly lipophilic, they are insoluble in H₂O. However, and quite unexpectedly, these compounds were found to be soluble in aqueous solutions of both anionic and non-ionic detergents at concentrations routinely used in topical applications. 25 This property of these compounds makes them suitable as topical antimicrobial and antiinflammatory agents.

Accordingly, the compounds of this invention may be incorporated into formulations for topical application. Such applications include, but are not limited to, 30 topical formulations the treatment of infection of mouth, skin, scalp, ear, nose, eyes, vagina and rectum. The infections treated by these compounds includes various disorders including gingivitis and acne.

The compounds of this invention may also be used as topical antimicrobial or antiinflammatory agents for veterinary use for the relief of infections in various conditions including gingivitis, conjunctivitis and 5 arthritis. The formulations can be applied to, without limitation, mouth, skin, scalp, ear, nose, eyes, vagina and rectum.

The method in accordance with the present invention for the relief of infection or inflammation comprises 10 contacting the affected area with the compounds of this invention in a pharmaceutically acceptable carrier containing alcohols, nonionic or ionic detergent. Such a carrier base may be selected from the group consisting of petroleum jelly, lanolin, paraffin wax, alkanols and 15 mixtures thereof. By using a base such as lanolin or petroleum jelly, a spreadable formulation is obtained and by using a base such as paraffin wax, a stick for topical application is obtained. In addition, the compounds of this invention may also be incorporated 20 into liquid carriers containing alcohols, non-ionic or ionic detergents. Thus, ethanol, the non-ionic detergent, Tween 80TM and the anionic detergent, sodium lauryl sulfate (SLS) may be used.

The above compounds can be used as antimicrobial or 25 antiinflammatory agents in mammals, particularly humans, by topical application of formulations containing the compounds of the present invention. These compounds can be used, without limitation, in tooth pastes, mouth rinses, soaps, shampoos, skin ointments, skin lotions, 30 eye ointments, eye drops, ear drops, and nasal drops.

In addition to the effect of the present compounds on the bacteria associated with dental plaques, another unexpected observation is that these compounds were also found to be effective against bacteria other than those 35 associated with the oral cavity. Accordingly, the drug formulations of the present invention can be used for

- 10 -

relief of systemic infections. Thus, these compounds can be used with pharmaceutical carriers suitable for delivery of lipophilic drugs such as, but not limited to, liposomal formulations or aerosols.

5 Liposomes are phospholipid vesicles which form closed fluid filled spheres when dispersed in aqueous solutions. Phospholipid molecules are polar molecules having a hydrophilic head toward the aqueous side and two hydrophobic tails made of fatty acid chains. At 10 sufficient concentrations, the phospholipid molecules organize into micells with polar heads point toward the aqueous medium and the fatty acid chains point toward the interior of the micelle. Various types of liposomal preparation techniques are described in U.S. patent no. 15 5,958,449, the disclosure of which is incorporated herein by reference. Liposomes may be delivered via routes such as intravenous, subcutaneous and topical. The liposomes may also be directed to target areas with the use of specific targeting agents such as by 20 incorporating specific recognition molecules in the liposomes.

Another method of delivery of the formulations of compounds of the present invention, including liposomal formulations, is via aerosols. Appropriate 25 concentrations for any particular mode of delivery and application will vary with the condition being treated. Determination of such concentrations are well within the purview of one skilled in the art.

The following examples illustrate the invention.

30

Example 1

This example illustrates the synthesis of 2-Hydroxy-5-(naphthalene-1-carbonyl)-N-phenyl-benzamide designated herein as NAI in a two-step process.

Synthesis of 2-Hydroxy-5-(naphthalene-1-carbonyl)-35 benzoic acid phenyl ester

The reaction vessel was a 500 ml three neck round bottom pyrex flask fitted with a 250 mL addition funnel, thermometer, a reflux condenser, and a stirrer. Aluminum chloride (7.98g, 59.8 mmole) and 225 mL of chloroform 5 were added into the round bottom flask and then this stirred suspension was cooled to 5°C with an external ice-bath. Phenyl salicylate (5.83 g, 27.2 mmole) and naphthalene-1-carbonyl chloride (4.91 mL, 6.21 g, 32.6 mmole) were combined together with 130 mL of chloroform 10 and added dropwise over a hour and half to the stirred suspension. Upon this addition color changes were observed from colorless to light yellow then dark green and finally to dark brown. The temperature was maintained at 5-15°C during the addition period.

15 Following the addition the reaction mixture was heated to reflux for 48 hours and then allowed to stand at 22°C for eight hours.

The reaction mixture was slowly added to a stirred slurry of 50 mL of crushed ice to which 125 mL of 12N 20 HCl had been added. The organic layer was isolated in a 1-liter separatory funnel and was washed 5 times with distilled water. Purity was checked on TLC (silica gel plate) and the solvent used was 1:1 ratio of CH_2Cl_2 and hexane. Three spots were observed on TLC, the phenyl 25 ester was on the top and the product spot was in the middle.

Purification was achieved by using flash column chromatography on silica gel with the same solvent system described above. There resulted 3.75 g (31%) of 30 the desired product phenyl ester as a white solid, mp 82-84 °C. ^1H NMR (300MHz, CDCl_3) δ 7.276 (d, $J = 9.0$ Hz, 1H, ArH), 7.357 (d, $J = 3.1$ Hz, 2H, ArH), 7.459 (m, 2H, ArH), 7.617 (t, 2H, ArH), 7.732 (m, 5H, ArH), 8.120 (m, 1H, ArH), 8.206 (m, 3H, ArH), 8.903 (d, $J = 2.1$ Hz, 1H,

ArH), 11.254 (s, 1H, OH, D₂O exchangeable) IR (KBr) ν 1652.9, 1566.1, 1199.65 cm⁻¹.

Synthesis of 2-Hydroxy-5-(naphthalene-1-carbonyl)-N-phenyl-benzamide

5 Hydrogen chloride gas was slowly bubbled into a solution of 300 mg of aniline in 5 mL of isopropyl ether until the solution was saturated with hydrogen chloride. The resulting white precipitate of aniline hydrochloride salt was collected and dried. 0.0501 g of this salt, 10 together with 1.50 g, (4.07 mmole) of the phenyl ester, described above, and 0.459 mL (5.04 mmole) of aniline, was placed in a 50 mL round bottom flask fitted with a distilling head connected with dry argon gas. The reaction mixture was first purged with dry argon gas for 15 30 minutes then the temperature was raised to 90 °C with an external oil bath to melt the ester. Finally, the temperature was raised to 170 °C and was maintained at 170 °C for 12 hours. During this period the TLC was checked several times to make sure the reaction was 20 completed. Dry argon gas purge was used during the heating period.

25 Purity was checked by using TLC (silica gel plate) with 10:1 hexane and ethyl acetate. Four spots were observed on TLC, the target compound was the second spot from the bottom just a bit higher than aniline spot, and the color was light yellow.

30 Purification was achieved by using flash column chromatography on silica gel with 10:1 hexane to ethyl acetate solvent system. The product was collected and dried to give 0.398 g (27%) of light yellow solid, mp 100-104 °C. ¹H NMR (300MHz, DMSO-d₆) δ 6.846 (d, J = 7.5 Hz, 2H, ArH), 6.910 (m, 2H, ArH), 7.139 (m, 3H, ArH), 7.262 (m, 2H, ArH), 7.492 (m, 3H, ArH), 7.640 (m, 2H, ArH), 7.725 (m, 3H, ArH), 8.057 (m, 2H, ArH), 2.441 (s, 1H, ArH), 9.507 (s, 1H, OH, D₂O exchangeable), 10.617 (s,

1H, NH, D₂O exchangeable) IR (KBr) ν 3059.8, 1642.2,
1593.1 cm⁻¹.

Example 2

This embodiment demonstrates the effectiveness of
5 the compounds of the present invention against gram
positive bacteria. The MIC's for the compounds were
determined by a modified microdilution tube dilution
method described in "Methods for Dilution Antimicrobial
Susceptibility Tests for Bacteria that Grow Aerobically"
10 (National Committee for Clinical Laboratory Standards
Approved Standards, 1997, NCCLS document M7-A4). In
general the modifications were made because of the
unique growth requirements for the fastidious oral
organisms and for those bacteria that require anaerobic
15 conditions. Reference is also made to "Methods for
Antimicrobial Susceptibility of Anaerobic Bacteria"
(National Committee for Clinical Laboratory Standards
Approved Standards, 1997, NCCLS document M11-A4).

Briefly, the methods were as follows. Cultures
20 were grown for 18-24hrs (aerobic bacteria) or 48-72 hrs
(anaerobic bacteria) in the appropriate medium. For
aerobic bacteria full strength brain heart infusion
medium (BHI, Difco) was used. For anaerobic bacteria,
half strength BHI (18.5 g/L) was supplemented by adding
25 yeast extract (10 g/L), hemin (0.29 mL of a stock
solution containing 0.1 g/200mL dH₂O) and menadione (15
mL of a stock solution containing 0.15 mL in 30 mL 95%
EtOH) was used. Initial cultures were diluted to
approximately 1x10³ CFU/mL for use as an inoculum. Each
30 assay received 10 μ L of the inoculum. The drugs were
prepared from a stock solution contained in dimethyl
sulfoxide (DMSO) and diluted into the culture medium.
Final concentrations of the drugs ranged from 50 to 0.05
 μ g /assay. The tests were run in duplicate and were
35 incubated appropriately with regard to oxygen
requirements for 24 to 48hrs as required. Anaerobic


- 14 -

incubation was an atmosphere of 5% CO₂, 10% H₂, with the balance N₂. The lowest concentration of an antimicrobial agent at which no visible growth is noted was referred to as the MIC.

5 The compounds of the present invention used in this example NA1mF, NA1mC, NA2mF, NA2mC, NA1pC, NA1, NA1NpC, NA1pBz, NA1OHmF, NA1_3BnOPh, NA1mOPh and NA1mF2 have been described above. NA1pBz is a naphthylsalicylanilide of Formula 110 wherein Z is 10 benzoyl at the para position. NA1mOPh has the structure of Formula 110 wherein Z is phenoxy at the meta position and NA1-2mOMe has the structure of Formula 110 wherein Z is -OCH₃ at both the meta positions. The structure of TMF-12 is described in U.S. patent no. 6,117,859. BPAmF, 15 BPAmC and BBAmF are substituted or unsubstituted alkylsalicylanilides described in U.S. Patent no. 4,287,191. Their structures are also provided below

BPAmF has the following structure:


20



25

BPAmC has the following structure:


30



35

BBAmF has the following structure:

5



10 In Tables 1-5, NE indicates that the drug was not effective at a concentration >50 micrograms/ml and "--" indicates that the drug was not tested.

Table 1 - Gram Positive

| 15 | Drug Code | S. mutans | S. sanguis | S.saliv -arius | P.acnes 6922 | P.acnes 11828 |
|----|-----------|--------------|---------------|-------------------|-----------------|------------------|
| | NA1mF | 0.8 | 0.8 | 3.1 | 0.2 | 0.4 |
| | NA1mC | 3.1 | 6.3 | 50 | 6.3 | 6.3 |
| | NA2mF | NE | 0.8 | 50 | 0.4 | 0.4 |
| | NA2mC | 6.3 | 6.3 | 50 | 6.3 | 12.5 |
| 20 | NA2pC | 1.6 | 6.3 | 50 | 6.3 | 6.3 |
| | BPAmF | NE | NE | NE | 0.2 | 0.4 |
| | BPAmC | NE | NE | NE | 0.2 | 12.5 |
| | BBAmF | NE | NE | NE | 0.2 | 0.8 |
| | NA1 | 50 | NE | NE | 25 | NE |
| 25 | NA1NpC | NE | - | - | 0.4 | - |
| | NA1pBz | NE | - | - | NE | - |
| | NA1OHmF | 6.3 | - | - | 3.1 | - |
| | NA1-2mOMe | NE | - | - | NE | - |
| | NA1_3BnOP | NE | - | - | NE | - |
| 30 | NA1mOPh | NE | - | - | NE | - |
| | NAmF2 | 1.6 | - | - | 0.4 | - |
| | TMF-12 | NE | 12.5 | NE | 0.4 | 0.2 |

- 16 -

Table 2 - Gram Positive

| Drug Code | A.viscosus | S.aureus | Lact 7469 | M.luteus |
|-----------|------------|----------|-----------|----------|
| 5 | NA1mF | <0.1 | 1.6/3.1 | 0.4 |
| | NA1mC | 3.2 | 6.3/12.5 | 3.1 |
| | NA2mF | NE | NE | 1.6 |
| | NA2mC | 1.6 | NE | 12.5 |
| | NA2pC | 1.6 | 6.3 | 6.3 |
| | BPAmF | NE | NE | 3.1 |
| 10 | BPAmC | NE | NE | 12.5 |
| | BBAmF | NE | NE | 6.3 |
| | NA1 | 3.1 | 50 | - |
| | NA1NpC | 0.8 | NE | - |
| | NA1pBz | NE | NE | - |
| | NA1OHmF | 0.8 | NE | - |
| 15 | NA1-2mOMe | NE | NE | - |
| | NA1_3BnOP | 6.3 | NE | - |
| | NA1mOPh | NE | NE | - |
| | NAmF2 | 0.8 | NE | - |
| | TMF-12 | 1.6 | NE | 3.1 |
| | | | | 0.8 |
| 20 | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |

- 17 -

Example 3

This embodiment demonstrates that effectiveness of the compounds of the present invention against gram negative bacteria. The method used was the same as 5 described in Example 1.

Table 3 - Gram Negative

| Drug Code | Fuso. 25586 | Aa Y4 | P.ging 381 | Pg 53977 | B.frag- ilis |
|-----------|----------------|-------|---------------|-------------|-----------------|
| NA1mF | 3.1 | 3.1 | <0.1 | <0.1 | 3.1 |
| NA1mC | 2.5 | 6.3 | 0.4 | 0.8 | NE |
| NA2mF | NE | NE | <0.4 | <0.4 | NE |
| NA2mC | NE | NE | 0.8 | 0.8 | 3.1 |
| NA2pC | 12.5 | 6.3 | 0.4 | 0.4 | 3.1 |
| BPAmF | NE | NE | <0.4 | <0.4 | 50 |
| BPAmC | NE | NE | <0.4 | <0.4 | 50 |
| BBAmF | NE | NE | <0.4 | <0.4 | NE |
| NA1 | - | - | 1.6 | - | - |
| NA1NpC | - | - | 0.2 | - | - |
| NA1pBz | - | - | NE | - | - |
| NA1OHmF | - | - | 0.8 | - | - |
| NA1-2mOMe | - | - | NE | - | - |
| NA1_3BnOP | - | - | 3.1 | - | - |
| NA1mOPh | - | - | NE | - | - |
| NAmF2 | - | - | 0.2 | - | - |
| TMF-12 | NE | NE | 0.4 | 0.4 | NE |

Table 4 - Gram negative

| Drug Code | S.pyo 51339 | S.pyo 49399 | S.pyo 19615 | Str.pn 6303 | Str.pn 6301 | Str.pn 6305 |
|-----------|----------------|----------------|----------------|----------------|----------------|----------------|
| NA1mF | 1.6 | 0.78 | 0.63 | 0.18 | 0.78 | 0.39 |
| NA1mC | 12.5 | 12.5 | 25 | 0.18 | 1.56 | 1.56 |

| | | | | | | | |
|----|-----------|------|------|------|------|------|------|
| | NA2mF | 0.4 | 3.2 | NE | 0.18 | 0.78 | 1.56 |
| | NA2mC | NE | NE | NE | 6.78 | 1.56 | 0.39 |
| | NA2pC | 3.2 | 3.2 | NE | 0.18 | 0.78 | 0.78 |
| 5 | BPAmF | 6.3 | 6.3 | NE | 0.18 | 1.56 | 0.78 |
| | BPAmC | NE | NE | NE | 0.18 | 0.78 | 0.78 |
| | BBAmF | 6.3 | 6.3 | NE | 0.18 | 0.78 | 0.39 |
| | NA1 | - | 12.5 | - | - | - | - |
| | NA1NpC | - | 6.3 | - | - | - | - |
| | NA1pBz | - | NE | - | - | - | - |
| 10 | NA1OHmF | - | 3.1 | - | - | - | - |
| | NA1-2mOMe | - | NE | - | - | - | - |
| | NA1_3BnOP | - | 50 | - | - | - | - |
| | NA1mOPh | - | NE | - | - | - | - |
| | NAmF2 | - | 1.6 | - | - | - | - |
| 15 | TMF-12 | 0.32 | 0.8 | 0.32 | 0.78 | 0.39 | 0.78 |

None of the drugs tested were found to be effective against *Salmonella*, *E.coli*, *Sal.chsuis* and *Citrobacter* even at concentrations greater than 50 micrograms/mL.

20 NE denotes a lack of a detectable effect at 50 micrograms per ml.

Example 4

25 This embodiment illustrates the efficacy of the compounds of the present invention against *Streptococcus* strains. One of the strains, Str.pn.R was obtained from the Children's Hospital in Buffalo (strain 00-041-0614). It was isolated from the bronchial wash and was found to 30 be beta lactamase positive. The sensitivity of this strain was tested against several known antibiotics. The results indicated that it was sensitive to Clindamycin, Vancomycin, Trovaflox, Rifampin but

resistant to penicillin and erythromycin. The efficacy, measured as MIC values, is shown in Table 5.

5

Table 5 - Mean Streptococcus MIC values

| Drug Code | Str..pyo | Str.pn | Str.pn.R |
|-----------|----------|--------|----------|
| NA1mF | 1.0 | 0.45 | 0.78 |
| NA1mC | 16.67 | 1.10 | 12.5 |
| NA2mF | - | 0.84 | 0.78 |
| NA2mC | NE | 0.91 | 6.25 |
| NA2pC | - | 0.58 | 3.12 |
| BPAmF | - | 0.84 | NE |
| BPAmC | - | 0.58 | NE |
| BBAmF | - | 0.45 | NE |
| TMF-12 | 0.47 | 0.65 | 0.78 |

Example 5

This embodiment describes the sensitivity of various staphylococcus strains to the compounds of the present invention. The staphylococcus species R is a strain 00-045-1209 from the Children's Hospital in Buffalo. It was isolated from the peritoneal cavity (fluid culture) of an individual. It was coagulase negative. The sensitivity of this strain was tested against several known antibiotics. The results indicated that it was sensitive to vancomycin but resistant to amoxicillin, clindamycin, erythromycin, oxacillin, azithromycin, and cefotaxime. However, this strain was found to be sensitive to the compounds of the present invention with the highest effect being observed with NA1mF (Table 5).

- 20 -

The *S.aureus* R2 species is a strain 00-42-1066 from the Children's Hospital in Buffalo. It was isolated from a wound in an individual. It was coagulase negative. The sensitivity of this strain was tested 5 against several known antibiotics. The results indicated that it was sensitive to vancomycin but resistant to amoxicillin, clindamycin, erythromycin, oxacillin, azithromycin, and cefotaxime.

10

Table 5

| Drug Code | <i>S.aureus</i> | <i>S.species</i> R | <i>S.aureus</i> R2 |
|-----------|-----------------|--------------------|--------------------|
| NA1mF | 3.1 | 1.6 | 1.6 |
| NA1mC | 12.5 | 25.0 | 6.3 |
| NA2mF | NE | 25.0 | 25.0 |
| NA2mC | NE | NE | NE |
| NA2pC | 6.3 | 12.5 | NE |
| BPAmF | NE | NE | NE |
| BPAmC | NE | NE | NE |
| BBAmF | NE | NE | NE |
| TMF | NE | NE | NE |

Example 6

This embodiment illustrates that the 25 antiinflammatory effects of the compounds of the present invention is comparable to those of known antiinflammatory agents such as saliflor (TMF-12). For this illustration, the TPA mouse ear inflammation assay was used for acute inflammation as described in U.S. 30 patents 5,958,911 and 6,117,859 (incorporated herein by reference). To quantitate inflammation, ear biopsies were weighed six hours after treatment with TPA (positive control) and the simultaneous application of a compound of the present invention (NA1mF, NA2mF), TMF-12

- 21 -

or in the absence of TPA (negative control). The results of the experiment are shown in Figure 1.

Various embodiments are presented herein for illustrative purposes and are not to be construed as 5 restrictive. Modifications of the embodiments presented herein that are obvious to those skilled in the art are intended to be within the scope of the invention and the claims.

10


15

- 22 -

We claim:

1. A compound having the formula


5



wherein W is a substituted or unsubstituted naphthyl ring, wherein the substitution on the naphthyl ring W consists of replacing one or more -H with a moiety selected from the group consisting of -OH, alkyl containing 1-6 carbon atoms, O-alkyl containing 1-6 carbon atoms, branched alkyl containing 1-6 carbon atoms, cycloalkyl containing 1-6 carbon atoms and combinations thereof, wherein Y is selected from the group consisting of substituted or unsubstituted phenyl and substituted or unsubstituted naphthyl, wherein the substitution on the phenyl or naphthyl ring Y consists of replacing one or more -H with a moiety selected from the group consisting of cyano, trifluoromethyl, nitro, methoxy, phenoxy, benzoyl, phenoxyethyl and combinations thereof.

25 2. The compound of claim 1 having the following structure.

30



35

wherein Z is independently at each position selected from the group consisting of -H, -CF₃, -CN, -NO₂, methoxy, phenoxy, benzoyl and phenoxyethyl; or an isomer thereof.

5

3. The compound of claim 2, wherein Z is -CF₃ at the meta or para position.

10

4. The compound of claim 2, wherein Z is -CN at the meta or para position.

5. The compound of claim 2, wherein Z is -NO₂ at the meta or para position.

15

6. The compound of claim 2, wherein Z is a methoxy group at the para or meta position.

7. The compound of claim 2, wherein Z is phenoxy group at the meta or para position.

20

8. The compound of claim 2, wherein Z is benzoyl group at the meta or para position.


25

9. The compound of claim 2, wherein Z is phenoxyethyl at the meta or para position.

10. The compound of claim 2, wherein Z is CF₃ at both the meta positions.

11. The compound of claim 1, having the following structure


35



- 24 -

12. The compound of claim 1 having the following structure

5




10

13. The compound of claim 1 having the following structure

15


20



25

14. A method of treating a bacterial infection in an individual comprising contacting the infected area with a therapeutically effective amount of a compound of the following structure


30



35

wherein W is a substituted or unsubstituted naphthyl ring, wherein the substitution on the naphthyl ring W consists of replacing one or more -H with -OH, wherein Y is selected from the group consisting of 5 substituted or unsubstituted phenyl and substituted or unsubstituted naphthyl, wherein the substitution on the phenyl or naphthyl ring Y consists of replacing one or more -H with a moiety selected from the group consisting of cyano, trifluoromethyl, nitro, phenoxyethyl and 10 combinations thereof.

15. The method of claim 14, wherein the compound has following structure



or an isomer thereof.

16. The method of claim 15, wherein Z is -CN at the 25 meta or para position.

17. The method of claim 15, wherein Z is -NO₂ at the meta or para position.


30 18. The method of claim 15, wherein Z is -CF₃ at the meta or para position.

19. The method of claim 15, wherein Z is phenoxyethyl at the meta or para position.

- 26 -

20. The method of claim 14, wherein the compound has the following structure


5



10

21. The method of claim 14, wherein the compound has the following structure

15




20

22. The method of claim 14, wherein the compound has the following structure

25

30



35

23. The method of claim 14, wherein the bacterial infection is caused by organisms selected from the group


consisting of gram positive bacteria, gram negative bacteria and combinations thereof.

24. The method of claim 23, wherein the gram positive
5 bacteria are selected from the group consisting of
S. mutans, *S. sanguis*, *S. salivarius*, *P. acnes*, *A. viscosus*,
S. aureus, *L. rhamnosus*.

25. The method of claim 23, wherein the gram negative
10 bacteria are selected from the group consisting of *Sal.*
chuis, *Fuso. nucleatum*, *A. actinomycetemcomitans*, *E.*
coli, *P. gingivalis*, *B. fragilis* and *Citrobacter*.

26. A method of treating inflammation in an individual
15 comprising contacting the affected area with an amount
sufficient to ameliorate the inflammatory condition, of
a compound of the following formula:

20




wherein W is a substituted or unsubstituted
25 naphthyl ring, wherein the substitution on the naphthyl
ring W consists of replacing one or more -H with a
moiety selected from the group consisting of -OH, alkyl
containing 1-6 carbon atoms, O-alkyl containing 1-6
carbon atoms, branched alkyl containing 1-6 carbon
30 atoms, cycloalkyl containing 1-6 carbon atoms and
combinations thereof, wherein Y is selected from the
group consisting of substituted or unsubstituted phenyl
and substituted or unsubstituted naphthyl, wherein the
substitution on the phenyl or naphthyl ring Y consists
35 of replacing one or more -H with a moiety selected from

- 28 -

the group consisting of cyano, trifluoromethyl, nitro, methoxy, phenoxy, benzoyl, phenoxyethyl and combinations thereof.

5 27. The method of claim 26, wherein the compound has the following formula:

10



15

or an isomer thereof.




Figure 1

INTERNATIONAL SEARCH REPORT

International application No
PCT/USA1/02456

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7): C07C 255/65, 255/50; A61K 31/165, 31/265

US CL: 561/180, 160; 558/415; 514/621,522,586

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 564/180, 160; 558/415; 514/621,522,586

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CASONLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category* | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No |
|-----------|--|--|
| Y | US 4,742,083 A (RITCHIEY) 03 May 1988, column 3-4. | 1-3, 5-6, 11-12, 14-15, 17-18, 20, 22-27 |

Further documents are listed in the continuation of Box C

See patent family index

| | | |
|---|---|--|
| * Special categories of cited documents | "P" | Later document published after the international filing date or grants date and not in conflict with the application but used to understand the principle or theory underlying the invention |
| "A" | document defining the general state of the art which is not considered to be of particular relevance | |
| "E" | earlier document published on or after the international filing date | "N" |
| "T" | document which may throw doubt on priority claims, or which is cited to establish the publication date of another citation or other special reason (as specified) | "P" |
| "D" | document referring to or used in relation to a withdrawal or other means | "P" |
| "R" | document published prior to the international filing date but later than the priority date claimed | "N" |

Date of the actual completion of the international search

22 JANUARY 2002

Date of mailing of the international search report

14 MAR 2002

Name and mailing address of the USPTO's
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-2250

Authenticating officer
Dorethea Lawrence, Jr.
MAILING ADDRESS
Telephone No. (703) 305-1223

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.